Join us for the next speaker in Werfen's ongoing Autoimmunity Speaker Series. Presented by Kevin D. Deane, MD, PhD, this webinar explores the transition from isolated biomarker positivity to established RA, focusing on the concept of multi‑autoantibody expansion and its implications for serological profiling. Through a combined clinical and laboratory perspective, we will review how established markers such as RF and ACPA, together with emerging autoantibodies, inform risk stratification, diagnosis and early disease pathways. Emphasis will be placed on the latest scientific research in RA and pre-RA, assay considerations, and the opportunities—and limitations—of expanded serological profiling in current practice for both diagnosis of RA in individuals with active inflammatory arthritis, and in risk stratification for future RA. 

Kevin D. Deane, MD, PhD will:

• Discuss the natural history of rheumatoid arthritis development from its 'preclinical phase' through the development of a clinical diagnosis of RA (i.e. clinical RA)
• Outline the role of biomarkers, including autoantibodies, in the current prediction of future clinical RA as well as in optimizing the diagnosis of clinical RA
• Review the landscape of clinical trials in RA prevention 

Featured Speaker

Kevin D. Deane, MD, PhD

Rheumatologist and Professor of Medicine, University of Colorado

Credits

Instrumentation Laboratory is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Level of instruction: Intermediate.